Human biosynthetic insulin derived fro E. coli or yeast has virtually replaced insulin from bovine and porcine pancreas. The production process for recombinant insulin is estimated for E. coli and yeast, comprising:
• cost of insulin precursor
• cost for bioactivation and purification of the precursor to insulin
The worldwide insulin market for 2020 is given, producers and their market share discussed and the growth prospects for insulin are reviewed.